A new patch for delivering zanamivir to treat the flu
Official title: Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
Funded at Tsrl, INC. · NIH-11110770 · Data updated 2026-11-12
This study is testing a new skin patch that lets people with the flu easily apply zanamivir medicine themselves, making it a simpler and less invasive option than using inhalers, especially for those who have trouble breathing.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tsrl, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | August 16, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $999,746 |
| NIH project number | 4R44AI179506-02 |
| Project ID | NIH-11110770 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are at risk for influenza complications, particularly those with respiratory issues or those who have difficulty using inhalers.
✕Less likely to help
Patients who are not affected by influenza or those who do not have any respiratory complications may not benefit from this research.
What this research studies
This research focuses on developing a novel microarray patch that allows patients to self-administer zanamivir, a medication effective against certain strains of influenza. The patch aims to provide a more efficient and less invasive method of drug delivery compared to traditional inhalation methods, which can be unsuitable for patients with respiratory issues. By using transdermal delivery, the medication can enter the bloodstream directly, potentially improving treatment outcomes for flu patients. This approach seeks to address the limitations of current flu treatments, especially in cases where patients may have difficulty using inhalers.
Why it matters
Potential benefit: If successful, this research could provide a more effective and accessible treatment option for patients suffering from influenza.
How similar studies have gone: Previous research has shown promise in transdermal drug delivery systems, suggesting that this approach could be effective for delivering antiviral medications.
Where this research is happening
-
Tsrl, INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Lipka, Elke — Tsrl, INC.
- Study coordinator: Lipka, Elke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.